Women should have access to the medicines they need to live their best and fullest lives. Medicines360 is helping in a unique way.


Latest Updates

Press Releases

FDA Approves Medicines360’s LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Eight Years

FDA Approval of Extended Duration of Use Supports Medicines360’s Mission to Expand Women’s Access Nov. 14, 2022 SAN FRANCISCO – Medicines360, a global nonprofit organization with a mission to expand women’s access to quality medicines, announced today that the U.S. Food and Drug Administration (FDA) has approved Medicines360’s Supplemental New Drug Application (sNDA) to extend […]

Read More >
Press Releases

Medicines360 Calls on U.S. Congress to Pass Affordability is Access Act Without Delay 

Legislation will ensure people across the country can access and afford over-the-counter birth control options and plan their own reproductive lives, on their own terms   San Francisco, CA – Medicines360 applauds congressional health care leaders Sens. Patty Murray, Mazie Hirono, and Catherine Cortez Masto and Reps. Ayanna Pressley, Ami Bera, and Alexandria Ocasio-Cortez for authoring […]

Read More >

Defying Definitions and Breaking Down Barriers: Lessons from Medicines360’s Nonprofit Journey

Medicines360 has the unique distinction of being the longest-standing nonprofit pharmaceutical organization that has product available in the U.S. market. Its inception was an industry innovation, and its survival has required it to push boundaries and defy traditional definitions — all in service of improving health equity. For the Medicines360’s team, the value of this […]

Read More >
more updates

how we work

We’re reinventing the pharma business model: we identify areas in women’s health where patients face limited choices, develop medicines that expand women’s options and make them available in ways that close gaps in access.


We believe women should have access to medicines, regardless of their diverse needs. As we choose products for development and study them in robust clinical trials, we tackle areas where many women struggle with limited medicine choices.